ETI treatment alone did, however, have a significant anti-inflammatory effect reducing IL-8, IL-6, CXCL1 and GM-CSF secretion in a TNF-α-induced pro-inflammatory primary CF HBE cell model, which may translate to potentially useful inflammatory markers to investigate in serum, plasma or bronchoalveolar lavage of pwCF. The gene discussed is IL6; the disease is cystic fibrosis.